Loading...
Docoh

Precision Biosciences (DTIL)

Utility
Treatment of Retinitis Pigmentosa Using Engineered Meganucleases
12 May 22
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 26 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
12 May 22
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyara Antony, Victor Bartsevich
Filed: 19 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
5 May 22
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Filed: 19 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Transferrin Gene
21 Apr 22
Disclosed herein are engineered nucleases that bind and cleave a recognition sequence within intron 1 of a transferrin gene, and methods of using such engineered nucleases to produce a genetically-modified eukaryotic cell comprising a modified transferrin gene.
Cassandra Gorsuch, Derek Jantz, James Jefferson Smith, Clayton Beard
Filed: 10 Jan 20
Utility
Genetic Modification of the Hydroxyacid Oxidase 1 Gene for Treatment of Primary Hyperoxaluria
24 Mar 22
Disclosed are engineered nucleases that bind and cleave a recognition sequence within a hydroxyacid oxidase 1 (HAO1) gene.
Roshni Davey, Derek Jantz, James Jefferson Smith, Gary Owens
Filed: 20 Dec 19
Utility
Optimized Engineered Meganucleases Having Specificity for a Recognition Sequence In the Hepatitis B Virus Genome
24 Feb 22
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome.
James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
Filed: 20 Sep 21
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
10 Feb 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton
Filed: 26 Oct 21
Utility
Genetically-modified T Cells Comprising a Modified Intron In the T Cell Receptor Alpha Gene
9 Sep 21
The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene.
Derek Jantz, James Jefferson Smith, Clayton Beard
Filed: 25 May 21
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
19 Aug 21
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 8 Apr 21
Utility
Precise Deletion of Chromosomal Sequences In Vivo and Treatment of Nucleotide Repeat Expansion Disorders Using Engineered Nucleases
29 Jul 21
The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome.
James Jefferson Smith, Victor Bartsevich, Derek Jantz
Filed: 15 Jan 21
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
8 Jul 21
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Filed: 1 Mar 21
Utility
Engineered Meganucleases Specific for Recognition Sequences In the Hepatitis B Virus Genome
17 Jun 21
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 28 Oct 20
Utility
Dystrophin Gene Exon Deletion Using Engineered Nucleases
20 May 21
The invention relates to the field of molecular biology and recombinant nucleic acid technology.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 25 Sep 20
Utility
Recognition Sequences for I-crei-derived Meganucleases and Uses Thereof
6 May 21
Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided.
Derek Jantz, James Jefferson Smith
Filed: 7 Oct 20
Utility
Optimized Engineered Nucleases Having Specificity for the Human T Cell Receptor Alpha Constant Region Gene
22 Apr 21
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene.
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Filed: 11 Apr 19
Utility
Engineered Meganucleases with Recognition Sequences Found In the Human T Cell Receptor Alpha Constant Region Gene
25 Feb 21
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 9 Sep 20
Utility
Rationally-designed Single-chain Meganucleases with Non-palindromic Recognition Sequences
25 Feb 21
Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence.
James Jefferson Smith, Derek Jantz
Filed: 23 Oct 20
Utility
Engineered Meganucleases with Recognition Sequences Found In the Human BETA-2 Microglobulin Gene
4 Feb 21
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human beta-2 microglobulin gene.
Victor Bartsevich, Christina Pham, Aaron Martin, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 19 Oct 20
Utility
Treatment of Retinitis Pigmentosa Using Engineered Meganucleases
6 Jan 21
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 16 Jul 20
Utility
Co-stimulatory Domains for Use In Genetically-modified Cells
23 Dec 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 8 Sep 20
Patents are sorted by USPTO publication date, most recent first